Type B Insulin Resistance Syndrome

Autoimmune MONDO:0016464 Pathograph 13 Show in embeddings browser Autoimmune Disease Endocrine Disorder

A rare acquired autoimmune disorder in which polyclonal IgG autoantibodies directed against the insulin receptor cause extreme insulin resistance. The autoantibodies act as partial agonists of the receptor, so glycemic control is characteristically bimodal and titer-dependent: high antibody titers block insulin action and produce refractory hyperglycemia with hypercatabolism, severe acanthosis nigricans, and hyperandrogenism in women, whereas lower titers may stimulate the receptor and produce fasting/autoimmune hypoglycemia. The syndrome has been reported most often in middle-aged women (classically of African ancestry) and is frequently associated with systemic autoimmune disease. It is one of the classic "extreme insulin resistance" syndromes, distinguished from the genetic (type A, Donohue, Rabson-Mendenhall) forms by its autoimmune, acquired basis. Treatment centers on immunomodulation to suppress pathogenic autoantibody production.

Ask OpenScientist

Ask a research question about Type B Insulin Resistance Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

5
Pathophys.
8
Phenotypes
13
Pathograph
8
Medical Actions
7
References
⚙

Pathophysiology

5
Pathogenic Anti-Insulin-Receptor Autoantibody Production
Autoreactive B-cell and plasma-cell activity produces the pathogenic IgG autoantibodies directed against the insulin receptor. This cellular source is the principal target of combination immunomodulatory therapy.
B cell CL:0000236 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves B cell (CL:0000236). CL:0000236 is a cell type from the Cell Ontology. Plasma cell CL:0000786 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Plasma cell (CL:0000786). CL:0000786 is a cell type from the Cell Ontology.
Immunoglobulin production GO:0002377 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Immunoglobulin production (GO:0002377). GO:0002377 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Anti-Insulin Receptor Autoantibodies Autoantibody production generates the circulating receptor-directed IgG lesion.
Show evidence (1 reference)
PMID:20484479 SUPPORT Human Clinical
"This report focuses on seven patients who were treated with an intensive combination protocol of rituximab, cyclophosphamide, and pulse corticosteroids aimed at control of pathogenic autoantibody production."
Directly identifies pathogenic autoantibody production as the therapeutic target.
Anti-Insulin Receptor Autoantibodies
Circulating IgG autoantibodies directed against the cell-surface insulin receptor are the defining acquired autoimmune lesion. Antibody concentration determines opposing hyperglycemic and hypoglycemic receptor effects.
Downstream
High-Titer Insulin Receptor Antagonism At high titer, the receptor-directed antibodies predominantly antagonize insulin action.
Low-Titer Insulin Receptor Agonism At low titer, the same receptor-directed antibodies can act as insulin mimetics.
Show evidence (2 references)
PMID:42438801 SUPPORT Human Clinical
"Type B insulin resistance syndrome (IRS) is a rare autoimmune disorder characterized by severe insulin resistance caused by autoantibodies against the insulin receptor."
Establishes the primary autoimmune lesion — autoantibodies against the insulin receptor as the cause of the syndrome.
PMID:20484479 SUPPORT Human Clinical
"Type B insulin resistance belongs to a class of diseases caused by an autoantibody to a cell surface receptor."
Classifies type B insulin resistance among autoantibody-to-cell-surface-receptor diseases, supporting the humoral autoimmune mechanism.
High-Titer Insulin Receptor Antagonism
At high antibody titer, insulin-receptor binding predominantly blocks insulin action and initiates the severe insulin-resistant, hyperglycemic state.
Downstream
Impaired Insulin Receptor Signaling At high antibody titer, receptor blockade impairs downstream insulin signaling, driving extreme insulin resistance and hyperglycemia.
Show evidence (1 reference)
PMID:42255432 SUPPORT Human Clinical
"These antibodies act as partial agonists, resulting in severe insulin resistance and hyperglycemia at high titer, and hypoglycemia at low titer."
Directly documents the partial-agonist behavior of the anti-receptor antibodies and the titer-dependent bimodal glycemic consequence.
Low-Titer Insulin Receptor Agonism
At low antibody titer, partial agonism of the insulin receptor can mimic insulin action and produce spontaneous hypoglycemia without exogenous insulin.
Downstream
Autoimmune Hypoglycemia Low-titer receptor agonism can drive spontaneous, sometimes intractable hypoglycemia.
Show evidence (1 reference)
PMID:42255432 SUPPORT Human Clinical
"These antibodies act as partial agonists, resulting in severe insulin resistance and hyperglycemia at high titer, and hypoglycemia at low titer."
Supports the low-titer receptor-agonist state.
Impaired Insulin Receptor Signaling
Antibody-mediated blockade of the insulin receptor impairs the downstream insulin receptor signaling pathway in insulin target tissues including liver, skeletal muscle, and adipose tissue.
Hepatocyte CL:0000182 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Hepatocyte (CL:0000182). CL:0000182 is a cell type from the Cell Ontology. Adipocyte CL:0000136 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Adipocyte (CL:0000136). CL:0000136 is a cell type from the Cell Ontology. Skeletal muscle cell CL:0000188 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Skeletal muscle cell, annotated with cell of skeletal muscle (CL:0000188). CL:0000188 is a cell type from the Cell Ontology.
Insulin receptor signaling pathway GO:0008286 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased Insulin receptor signaling pathway (GO:0008286). GO:0008286 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Severe Insulin Resistance Impaired insulin action produces the defining extreme insulin-resistant state.
Refractory Hyperglycemia Loss of insulin action produces severe, often refractory hyperglycemia.
Acanthosis Nigricans Severe loss of insulin action is associated with marked acanthosis nigricans.
Hyperandrogenism In affected women, the severe insulin-resistant state can produce hyperandrogenism.
Weight Loss Failure of insulin action produces a hypercatabolic state with severe weight loss.
Show evidence (2 references)
PMID:20484479 SUPPORT Human Clinical
"Blockade of insulin action results in hyperglycemia, hypercatabolism, severe acanthosis nigricans, and hyperandrogenism in women."
Links receptor blockade to the downstream metabolic and dermatologic phenotype of the syndrome.
PMID:27254267 SUPPORT Other
"refractory transient hyperglycemia and extreme insulin resistance are the cardinal features, but hypoglycemia may also occur"
Identifies refractory hyperglycemia and extreme insulin resistance as the cardinal metabolic consequences.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Type B Insulin Resistance Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

8
Endocrine 2
Hyperandrogenism Increased circulating androgen concentration HP:0030348 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hyperandrogenism, annotated with Increased circulating androgen concentration (HP:0030348). HP:0030348 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20484479 SUPPORT Human Clinical
"Blockade of insulin action results in hyperglycemia, hypercatabolism, severe acanthosis nigricans, and hyperandrogenism in women."
Names hyperandrogenism in women as a feature of the syndrome.
Diabetic Ketoacidosis HP:0001953 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Diabetic ketoacidosis (HP:0001953). HP:0001953 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:42255432 SUPPORT Human Clinical
"We report a 20-year-old Hispanic woman who presented with diabetic ketoacidosis (DKA), severe refractory hyperglycemia, and extreme insulin resistance requiring high doses of U-500 insulin."
Directly documents DKA as the presenting manifestation in a confirmed type B insulin resistance case.
Immune 1
Autoimmunity HP:0002960 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autoimmunity (HP:0002960). HP:0002960 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27254267 SUPPORT Other
"This disorder is most frequently reported in middle-aged black women and is invariably associated with other autoimmune diseases."
Narrative review supports structured representation of the autoimmune host context while newer cases caution against treating the demographic as exclusive.
Integument 1
Acanthosis Nigricans HP:0000956 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Acanthosis nigricans (HP:0000956). HP:0000956 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20484479 SUPPORT Human Clinical
"Blockade of insulin action results in hyperglycemia, hypercatabolism, severe acanthosis nigricans, and hyperandrogenism in women."
Names severe acanthosis nigricans as a consequence of insulin-receptor blockade.
Metabolism 3
Severe Insulin Resistance HP:0000855 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Insulin resistance (HP:0000855), qualified as severity severe. HP:0000855 is a phenotype from the Human Phenotype Ontology.
Severity: SEVERE
Show evidence (1 reference)
PMID:27254267 SUPPORT Other
"refractory transient hyperglycemia and extreme insulin resistance are the cardinal features, but hypoglycemia may also occur"
Extreme insulin resistance is named as a cardinal feature of the syndrome.
Refractory Hyperglycemia HP:0003074 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hyperglycemia (HP:0003074). HP:0003074 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:42255432 SUPPORT Human Clinical
"She had cachexia, acanthosis nigricans, and persistent hyperglycemia despite intravenous insulin infusion exceeding 4 units/kg/day."
Documents refractory hyperglycemia persisting despite extraordinarily high insulin infusion rates.
Autoimmune Hypoglycemia HP:0001943 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypoglycemia (HP:0001943). HP:0001943 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:29264467 SUPPORT Human Clinical
"fluctuating glucose levels (ranging from hyperglycemia with extreme insulin resistance to intractable hypoglycemia without exogenous insulin administration)"
Documents intractable hypoglycemia without exogenous insulin as part of the fluctuating glycemic course.
PMID:37552775 SUPPORT Human Clinical
"Isolated hypoglycemia with low insulin forms a rare subgroup of type B insulin resistance. These patients lack the common characteristics of hyperinsulinemic hypoglycemia and hyperglycemia/insulin resistance. Furthermore, while coexisting autoimmune disease is commonly observed, there is..."
A systematic review defines the low-insulin isolated-hypoglycemia subgroup and reports a possible delayed association with aggressive lymphoma.
Growth 1
Weight Loss HP:0001824 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Weight loss (HP:0001824). HP:0001824 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:42255432 SUPPORT Human Clinical
"She had cachexia, acanthosis nigricans, and persistent hyperglycemia despite intravenous insulin infusion exceeding 4 units/kg/day."
Documents cachexia (weight loss/hypercatabolism) accompanying the hyperglycemic phase.
💊

Medical Actions

8
Combination Immunomodulatory Therapy (Rituximab, Cyclophosphamide, Pulse Corticosteroids)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: rituximab NCIT:C1702 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses rituximab (NCIT:C1702). NCIT:C1702 is a therapeutic agent from the NCI Thesaurus. cyclophosphamide NCIT:C405 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses cyclophosphamide (NCIT:C405). NCIT:C405 is a therapeutic agent from the NCI Thesaurus. corticosteroid CHEBI:50858 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses corticosteroid (CHEBI:50858). CHEBI:50858 is a therapeutic agent from Chemical Entities of Biological Interest.
The NIH combination protocol of rituximab, cyclophosphamide, and pulse corticosteroids is aimed at suppressing pathogenic anti-insulin-receptor autoantibody production and induced remission in the reported cohort.
Mechanism Target:
INHIBITS Pathogenic Anti-Insulin-Receptor Autoantibody Production — Combination immunomodulation is directed at controlling the pathogenic insulin-receptor autoantibody burden.
Show evidence (1 reference)
PMID:20484479 SUPPORT Human Clinical
"This report focuses on seven patients who were treated with an intensive combination protocol of rituximab, cyclophosphamide, and pulse corticosteroids aimed at control of pathogenic autoantibody production."
Directly supports the regimen targeting pathogenic autoantibody production.
Show evidence (2 references)
PMID:20484479 SUPPORT Human Clinical
"This report focuses on seven patients who were treated with an intensive combination protocol of rituximab, cyclophosphamide, and pulse corticosteroids aimed at control of pathogenic autoantibody production."
Describes the combination immunomodulatory protocol and its rationale.
PMID:20484479 SUPPORT Human Clinical
"All seven treated patients achieved remission, defined as amelioration of hyperglycemia, discontinuation of insulin therapy, and resolution of hyperandrogenism."
Documents remission of the metabolic and endocrine phenotype after the protocol.
Glucocorticoid Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: corticosteroid CHEBI:50858 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses corticosteroid (CHEBI:50858). CHEBI:50858 is a therapeutic agent from Chemical Entities of Biological Interest.
Glucocorticoids are used to suppress autoantibody production; their addition can produce rapid clinical improvement and a marked fall in insulin receptor autoantibody titers.
Show evidence (1 reference)
PMID:42438801 SUPPORT Human Clinical
"The addition of glucocorticoid therapy resulted in rapid clinical improvement and marked reduction in the insulin receptor autoantibody titers"
Documents glucocorticoid-induced improvement and autoantibody titer reduction.
Plasmapheresis
Action: PlasmapheresisNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Plasmapheresis (NCIT:C15304). NCIT:C15304 is a clinical intervention from the NCI Thesaurus. NCIT:C15304
Therapeutic plasma exchange has been used with variable outcomes in patients without spontaneous remission.
Show evidence (1 reference)
PMID:29264467 SUPPORT Human Clinical
"Treatments with high-dose steroids, immunosuppressants, and plasmapheresis have been used, with variable outcomes, in patients without spontaneous remission."
Lists plasmapheresis among treatments used, with variable outcomes.
High-Dose Insulin Therapy (Supportive)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: insulin CHEBI:145810 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses insulin (CHEBI:145810). CHEBI:145810 is a therapeutic agent from Chemical Entities of Biological Interest.
Very high doses of exogenous insulin (including concentrated U-500 insulin and intravenous infusion) are used to control hyperglycemia during the insulin-resistant phase, though hyperglycemia is often refractory.
Show evidence (2 references)
PMID:29264467 SUPPORT Human Clinical
"Treatment in the hyperglycemic phase is usually with high doses of insulin (average, 5100 U/d in some studies)"
Human clinical review supports high-dose insulin as supportive therapy during the hyperglycemic phase.
PMID:42255432 SUPPORT Human Clinical
"She had cachexia, acanthosis nigricans, and persistent hyperglycemia despite intravenous insulin infusion exceeding 4 units/kg/day."
Illustrates the use of very high-dose intravenous insulin and its frequent inadequacy, supporting insulin as supportive (not curative) therapy.
Metformin with low-dose semaglutide
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Adjunctive metformin and a GLP-1 receptor agonist can reduce the extraordinary insulin requirement during the severe hyperglycemic phase. Evidence is currently limited to a case report, so this is supportive rather than disease-modifying care.
Show evidence (1 reference)
PMID:42255432 SUPPORT Human Clinical
"Adjunctive therapy with metformin and low-dose semaglutide reduced daily insulin requirements from over 5,000 units to 200 units."
Directly reports a large insulin-dose reduction with this adjunctive combination in one TBIR case.
Rituximab and azathioprine immunosuppression
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Rituximab with azathioprine is an alternative reported immunosuppressive combination aimed at controlling pathogenic autoantibody production.
Mechanism Target:
INHIBITS Pathogenic Anti-Insulin-Receptor Autoantibody Production — The regimen suppresses the cellular production of pathogenic receptor autoantibodies.
Show evidence (1 reference)
PMID:42255432 SUPPORT Human Clinical
"Subsequent treatment with rituximab and azathioprine led to complete discontinuation of insulin within one week."
Human response supports immunosuppression of the pathogenic autoantibody-producing process.
Show evidence (1 reference)
PMID:42255432 SUPPORT Human Clinical
"Subsequent treatment with rituximab and azathioprine led to complete discontinuation of insulin within one week."
Directly reports insulin discontinuation after the regimen.
Diazoxide for recurrent hypoglycemia
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Low-dose diazoxide can be used to control recurrent fasting hypoglycemia in the agonistic/low-titer phase when hypoglycemia recurs after steroid taper.
Show evidence (1 reference)
PMID:42255432 SUPPORT Human Clinical
"However, the course was complicated by serum sickness-like illness and recurrent fasting hypoglycemia, which was managed with glucocorticoids and diazoxide."
Directly supports diazoxide in the recurrent hypoglycemic phase of the reported case.
Continuous glucose monitoring
Action: continuous blood glucose assessmentNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is continuous blood glucose assessment, annotated with Blood Glucose Measurement (NCIT:C92744). NCIT:C92744 is a clinical intervention from the NCI Thesaurus. Ontology label: Blood Glucose Measurement NCIT:C92744
Continuous glucose monitoring supports dynamic insulin titration across the hyperglycemic phase and early detection of transition to severe hypoglycemia.
Show evidence (1 reference)
PMID:42255432 SUPPORT Human Clinical
"Continuous glucose monitoring proved essential in guiding therapy and preventing severe hypoglycemia."
Directly supports CGM for treatment guidance and safety in biphasic TBIR.
🔬

Biochemical Markers

3
Insulin Receptor Autoantibodies
Show evidence (1 reference)
PMID:42438801 SUPPORT Human Clinical
"Markedly elevated insulin receptor autoantibody titers (85.9%) confirmed the diagnosis of type B IRS."
Insulin receptor autoantibody titer is the confirmatory diagnostic marker.
Hyperinsulinemia
Show evidence (1 reference)
PMID:29264467 SUPPORT Human Clinical
"high serum insulin levels, and insulin receptor autoantibodies"
Documents high serum insulin levels as a laboratory feature of the syndrome.
Elevated adiponectin
Show evidence (1 reference)
PMID:42255432 SUPPORT Human Clinical
"Laboratory findings showed elevated C-peptide and adiponectin, with positive antinuclear and anti-Smith ribonucleoprotein antibodies."
Directly documents elevated adiponectin and C-peptide in a confirmed TBIR case.
🔬

Diagnosis

2
Insulin receptor autoantibody testing
Detection of circulating insulin receptor autoantibodies confirms type B insulin resistance in a compatible acquired syndrome of extreme insulin resistance, glycemic fluctuation, and autoimmune disease.
laboratory procedure NCIT:C25294 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:42438801 SUPPORT Human Clinical
"Markedly elevated insulin receptor autoantibody titers (85.9%) confirmed the diagnosis of type B IRS."
A human case directly identifies the confirmatory antibody test.
Clinical and metabolic pattern recognition
The diagnostic pattern includes extreme insulin resistance or spontaneous hypoglycemia, high insulin in the classic phenotype, acanthosis nigricans, and a frequent coexisting systemic autoimmune disorder. The rare isolated hypoglycemia subgroup may instead have suppressed insulin.
clinical assessment NCIT:C124351 NCI Thesaurus (NCIT)
Show evidence (5 references)
PMID:27254267 SUPPORT Other
"Typically, refractory transient hyperglycemia and extreme insulin resistance are the cardinal features, but hypoglycemia may also occur."
Review states the cardinal clinical-metabolic diagnostic pattern.
PMID:37552775 SUPPORT Human Clinical
"Isolated hypoglycemia with low insulin forms a rare subgroup of type B insulin resistance."
Systematic review prevents the classic high-insulin pattern from being treated as universal.
PMID:29264467 SUPPORT Human Clinical
"glucose levels (ranging from hyperglycemia with extreme insulin resistance to intractable hypoglycemia without exogenous insulin administration), high serum insulin levels, and insulin receptor autoantibodies."
Human case review supports the classic fluctuating glucose, hyperinsulinemia, and receptor-autoantibody pattern.
+ 2 more references
📈

Progression

2
High-titer insulin-resistant phase
Age: Acquired disease, most often reported in adulthood
High antibody titers can produce abrupt or refractory hyperglycemia, extreme insulin resistance, cachexia, and very high insulin requirements.
Show evidence (2 references)
PMID:42255432 SUPPORT Human Clinical
"She had cachexia, acanthosis nigricans, and persistent hyperglycemia despite intravenous insulin infusion exceeding 4 units/kg/day."
A human case documents the severe high-titer clinical phase.
PMID:42255432 SUPPORT Human Clinical
"These antibodies act as partial agonists, resulting in severe insulin resistance and hyperglycemia at high titer, and hypoglycemia at low titer."
Supports the antibody-titer framing of the insulin-resistant phase.
Low-titer hypoglycemic phase
Age: May follow or alternate with the insulin-resistant phase
As antibody concentration and functional balance change, patients may transition to spontaneous fasting or recurrent hypoglycemia; isolated low-insulin hypoglycemia is a rare subgroup.
Show evidence (1 reference)
PMID:42255432 SUPPORT Human Clinical
"This biphasic glycemic course underscores the complex immunopathophysiology of TBIR."
The report explicitly characterizes the hyperglycemia-to-hypoglycemia course as biphasic.
📊

Prevalence

1
Worldwide
Unknown
The syndrome is rare, and available literature does not establish a denominator-based prevalence estimate or a well-defined natural history.
Show evidence (1 reference)
PMID:29264467 SUPPORT Human Clinical
"The exact prevalence and disease course are not well known because of the rarity of this syndrome."
The review explicitly states that prevalence is unknown.
⚖️

Clinical Burden

High
Extreme insulin resistance may require thousands of insulin units per day, while a later hypoglycemic phase can be refractory and fatal. Management requires vigilant glucose monitoring and immunosuppression, and historical mortality was strongly associated with hypoglycemia despite modern gains.
Show evidence (2 references)
PMID:27254267 SUPPORT Other
"Traditionally, the high reported mortality rate was typically attributed to the hypoglycemia."
Review supports the high burden and mortality associated with the hypoglycemic phase.
PMID:29264467 SUPPORT Human Clinical
"Treatment in the hyperglycemic phase is usually with high doses of insulin (average, 5100 U/d in some studies)"
Supports the exceptionally intensive treatment burden of the hyperglycemic phase.
{ }

Source YAML

click to show 
name: Type B Insulin Resistance Syndrome
creation_date: "2026-07-25T00:00:00Z"
category: Autoimmune
parents:
- Autoimmune Disease
- Endocrine Disorder
disease_term:
  preferred_term: Type B Insulin Resistance Syndrome
  term:
    id: MONDO:0016464
    label: insulin-resistance syndrome type B
description: >-
  A rare acquired autoimmune disorder in which polyclonal IgG autoantibodies
  directed against the insulin receptor cause extreme insulin resistance. The
  autoantibodies act as partial agonists of the receptor, so glycemic control is
  characteristically bimodal and titer-dependent: high antibody titers block
  insulin action and produce refractory hyperglycemia with hypercatabolism,
  severe acanthosis nigricans, and hyperandrogenism in women, whereas lower
  titers may stimulate the receptor and produce fasting/autoimmune hypoglycemia.
  The syndrome has been reported most often in middle-aged women (classically
  of African ancestry) and is frequently associated with systemic autoimmune
  disease. It is one of the classic "extreme
  insulin resistance" syndromes, distinguished from the genetic (type A,
  Donohue, Rabson-Mendenhall) forms by its autoimmune, acquired basis. Treatment
  centers on immunomodulation to suppress pathogenic autoantibody production.
pathophysiology:
- name: Pathogenic Anti-Insulin-Receptor Autoantibody Production
  role: TRIGGER
  biological_scale: CELLULAR
  description: >-
    Autoreactive B-cell and plasma-cell activity produces the pathogenic IgG
    autoantibodies directed against the insulin receptor. This cellular source
    is the principal target of combination immunomodulatory therapy.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: Plasma cell
    term:
      id: CL:0000786
      label: plasma cell
  biological_processes:
  - preferred_term: Immunoglobulin production
    term:
      id: GO:0002377
      label: immunoglobulin production
    modifier: INCREASED
  downstream:
  - target: Anti-Insulin Receptor Autoantibodies
    description: Autoantibody production generates the circulating receptor-directed IgG lesion.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20484479
      reference_title: "Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This report focuses on seven patients who were treated with an intensive combination protocol of rituximab, cyclophosphamide, and pulse corticosteroids aimed at control of pathogenic autoantibody production."
      explanation: The response to a regimen explicitly aimed at production supports this cellular source of the pathogenic antibodies.
  evidence:
  - reference: PMID:20484479
    reference_title: "Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This report focuses on seven patients who were treated with an intensive combination protocol of rituximab, cyclophosphamide, and pulse corticosteroids aimed at control of pathogenic autoantibody production."
    explanation: Directly identifies pathogenic autoantibody production as the therapeutic target.
- name: Anti-Insulin Receptor Autoantibodies
  role: CENTRAL_EFFECTOR
  biological_scale: MOLECULAR
  description: >-
    Circulating IgG autoantibodies directed against the cell-surface insulin
    receptor are the defining acquired autoimmune lesion. Antibody concentration
    determines opposing hyperglycemic and hypoglycemic receptor effects.
  downstream:
  - target: High-Titer Insulin Receptor Antagonism
    description: >-
      At high titer, the receptor-directed antibodies predominantly antagonize
      insulin action.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:42255432
      reference_title: "Type B insulin resistance with glycemic extremes: a case report and literature review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These antibodies act as partial agonists, resulting in severe insulin resistance and hyperglycemia at high titer, and hypoglycemia at low titer."
      explanation: Directly supports a high-titer antagonistic state causing severe insulin resistance and hyperglycemia.
  - target: Low-Titer Insulin Receptor Agonism
    description: At low titer, the same receptor-directed antibodies can act as insulin mimetics.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:42255432
      reference_title: "Type B insulin resistance with glycemic extremes: a case report and literature review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These antibodies act as partial agonists, resulting in severe insulin resistance and hyperglycemia at high titer, and hypoglycemia at low titer."
      explanation: Directly supports low-titer agonistic antibody activity and hypoglycemia.
  evidence:
  - reference: PMID:42438801
    reference_title: "Type B insulin resistance syndrome coexisting with aplastic anemia responsive to early immunosuppressive therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Type B insulin resistance syndrome (IRS) is a rare autoimmune disorder characterized by severe insulin resistance caused by autoantibodies against the insulin receptor."
    explanation: >-
      Establishes the primary autoimmune lesion — autoantibodies against the insulin
      receptor as the cause of the syndrome.
  - reference: PMID:20484479
    reference_title: "Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Type B insulin resistance belongs to a class of diseases caused by an autoantibody to a cell surface receptor."
    explanation: >-
      Classifies type B insulin resistance among autoantibody-to-cell-surface-receptor
      diseases, supporting the humoral autoimmune mechanism.
- name: High-Titer Insulin Receptor Antagonism
  role: CENTRAL_EFFECTOR
  biological_scale: MOLECULAR
  description: >-
    At high antibody titer, insulin-receptor binding predominantly blocks insulin
    action and initiates the severe insulin-resistant, hyperglycemic state.
  downstream:
  - target: Impaired Insulin Receptor Signaling
    description: >-
      At high antibody titer, receptor blockade impairs downstream insulin
      signaling, driving extreme insulin resistance and hyperglycemia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20484479
      reference_title: "Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Blockade of insulin action results in hyperglycemia, hypercatabolism, severe acanthosis nigricans, and hyperandrogenism in women."
      explanation: Directly supports loss of insulin action as the proximal consequence of receptor blockade.
  evidence:
  - reference: PMID:42255432
    reference_title: "Type B insulin resistance with glycemic extremes: a case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These antibodies act as partial agonists, resulting in severe insulin resistance and hyperglycemia at high titer, and hypoglycemia at low titer."
    explanation: >-
      Directly documents the partial-agonist behavior of the anti-receptor antibodies
      and the titer-dependent bimodal glycemic consequence.
- name: Low-Titer Insulin Receptor Agonism
  role: CENTRAL_EFFECTOR
  biological_scale: MOLECULAR
  description: >-
    At low antibody titer, partial agonism of the insulin receptor can mimic
    insulin action and produce spontaneous hypoglycemia without exogenous insulin.
  downstream:
  - target: Autoimmune Hypoglycemia
    description: Low-titer receptor agonism can drive spontaneous, sometimes intractable hypoglycemia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:42255432
      reference_title: "Type B insulin resistance with glycemic extremes: a case report and literature review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These antibodies act as partial agonists, resulting in severe insulin resistance and hyperglycemia at high titer, and hypoglycemia at low titer."
      explanation: Directly attributes hypoglycemia to low-titer partial agonism.
  evidence:
  - reference: PMID:42255432
    reference_title: "Type B insulin resistance with glycemic extremes: a case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These antibodies act as partial agonists, resulting in severe insulin resistance and hyperglycemia at high titer, and hypoglycemia at low titer."
    explanation: Supports the low-titer receptor-agonist state.
- name: Impaired Insulin Receptor Signaling
  role: CENTRAL_EFFECTOR
  biological_scale: CELLULAR
  description: >-
    Antibody-mediated blockade of the insulin receptor impairs the downstream
    insulin receptor signaling pathway in insulin target tissues including liver,
    skeletal muscle, and adipose tissue.
  cell_types:
  - preferred_term: Hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  - preferred_term: Adipocyte
    term:
      id: CL:0000136
      label: adipocyte
  - preferred_term: Skeletal muscle cell
    term:
      id: CL:0000188
      label: cell of skeletal muscle
  biological_processes:
  - preferred_term: Insulin receptor signaling pathway
    term:
      id: GO:0008286
      label: insulin receptor signaling pathway
    modifier: DECREASED
  downstream:
  - target: Severe Insulin Resistance
    description: Impaired insulin action produces the defining extreme insulin-resistant state.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:42255432
      reference_title: "Type B insulin resistance with glycemic extremes: a case report and literature review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These antibodies act as partial agonists, resulting in severe insulin resistance and hyperglycemia at high titer, and hypoglycemia at low titer."
      explanation: Directly links the high-titer antibody effect to severe insulin resistance.
  - target: Refractory Hyperglycemia
    description: Loss of insulin action produces severe, often refractory hyperglycemia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20484479
      reference_title: "Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Blockade of insulin action results in hyperglycemia, hypercatabolism, severe acanthosis nigricans, and hyperandrogenism in women."
      explanation: Directly links blockade of insulin action to hyperglycemia.
  - target: Acanthosis Nigricans
    description: Severe loss of insulin action is associated with marked acanthosis nigricans.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20484479
      reference_title: "Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Blockade of insulin action results in hyperglycemia, hypercatabolism, severe acanthosis nigricans, and hyperandrogenism in women."
      explanation: Directly names severe acanthosis nigricans as a result of insulin-action blockade.
  - target: Hyperandrogenism
    description: In affected women, the severe insulin-resistant state can produce hyperandrogenism.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20484479
      reference_title: "Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Blockade of insulin action results in hyperglycemia, hypercatabolism, severe acanthosis nigricans, and hyperandrogenism in women."
      explanation: Directly attributes hyperandrogenism in women to blockade of insulin action.
  - target: Weight Loss
    description: Failure of insulin action produces a hypercatabolic state with severe weight loss.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20484479
      reference_title: "Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Blockade of insulin action results in hyperglycemia, hypercatabolism, severe acanthosis nigricans, and hyperandrogenism in women."
      explanation: Directly attributes hypercatabolism to blockade of insulin action.
  evidence:
  - reference: PMID:20484479
    reference_title: "Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Blockade of insulin action results in hyperglycemia, hypercatabolism, severe acanthosis nigricans, and hyperandrogenism in women."
    explanation: >-
      Links receptor blockade to the downstream metabolic and dermatologic phenotype
      of the syndrome.
  - reference: PMID:27254267
    reference_title: "Type B insulin resistance syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "refractory transient hyperglycemia and extreme insulin resistance are the cardinal features, but hypoglycemia may also occur"
    explanation: >-
      Identifies refractory hyperglycemia and extreme insulin resistance as the cardinal
      metabolic consequences.
phenotypes:
- name: Severe Insulin Resistance
  description: >-
    Extreme, often refractory insulin resistance requiring very high exogenous
    insulin doses; a cardinal feature of the syndrome.
  phenotype_term:
    preferred_term: Insulin resistance
    term:
      id: HP:0000855
      label: Insulin resistance
    severity: SEVERE
  evidence:
  - reference: PMID:27254267
    reference_title: "Type B insulin resistance syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "refractory transient hyperglycemia and extreme insulin resistance are the cardinal features, but hypoglycemia may also occur"
    explanation: >-
      Extreme insulin resistance is named as a cardinal feature of the syndrome.
- name: Refractory Hyperglycemia
  description: >-
    Severe hyperglycemia that is often refractory to very high doses of exogenous
    insulin, corresponding to high autoantibody titers.
  phenotype_term:
    preferred_term: Hyperglycemia
    term:
      id: HP:0003074
      label: Hyperglycemia
  evidence:
  - reference: PMID:42255432
    reference_title: "Type B insulin resistance with glycemic extremes: a case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She had cachexia, acanthosis nigricans, and persistent hyperglycemia despite intravenous insulin infusion exceeding 4 units/kg/day."
    explanation: >-
      Documents refractory hyperglycemia persisting despite extraordinarily high insulin
      infusion rates.
- name: Autoimmune Hypoglycemia
  description: >-
    Fasting or intractable hypoglycemia without exogenous insulin, occurring when
    antibody titers are low and the autoantibodies act as receptor agonists.
    Historically a major driver of mortality. A rare subgroup has isolated
    hypoglycemia with suppressed, rather than elevated, insulin and may have a
    delayed association with aggressive lymphoma.
  phenotype_term:
    preferred_term: Hypoglycemia
    term:
      id: HP:0001943
      label: Hypoglycemia
  evidence:
  - reference: PMID:29264467
    reference_title: "Immunosuppressive Therapy in Treatment of Refractory Hypoglycemia in Type B Insulin Resistance: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "fluctuating glucose levels (ranging from hyperglycemia with extreme insulin resistance to intractable hypoglycemia without exogenous insulin administration)"
    explanation: >-
      Documents intractable hypoglycemia without exogenous insulin as part of the fluctuating
      glycemic course.
  - reference: PMID:37552775
    reference_title: "Systematic Review-Type B Insulin Resistance With Isolated Hypoglycemia and Suppressed Insulin."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Isolated hypoglycemia with low insulin forms a rare subgroup of type B insulin
      resistance. These patients lack the common characteristics of hyperinsulinemic
      hypoglycemia and hyperglycemia/insulin resistance. Furthermore, while coexisting
      autoimmune disease is commonly observed, there is potentially an association
      with aggressive lymphoma, the onset of which may be delayed.
    explanation: >-
      A systematic review defines the low-insulin isolated-hypoglycemia subgroup
      and reports a possible delayed association with aggressive lymphoma.
- name: Acanthosis Nigricans
  description: >-
    Hyperpigmented, velvety skin thickening characteristic of severe insulin
    resistance states, typically severe in type B insulin resistance.
  phenotype_term:
    preferred_term: Acanthosis nigricans
    term:
      id: HP:0000956
      label: Acanthosis nigricans
  evidence:
  - reference: PMID:20484479
    reference_title: "Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Blockade of insulin action results in hyperglycemia, hypercatabolism, severe acanthosis nigricans, and hyperandrogenism in women."
    explanation: >-
      Names severe acanthosis nigricans as a consequence of insulin-receptor blockade.
- name: Hyperandrogenism
  description: >-
    Signs of androgen excess (e.g., hirsutism, elevated testosterone) in affected
    women, reflecting the hyperinsulinemic/insulin-resistant state.
  phenotype_term:
    preferred_term: Hyperandrogenism
    term:
      id: HP:0030348
      label: Increased circulating androgen concentration
  evidence:
  - reference: PMID:20484479
    reference_title: "Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Blockade of insulin action results in hyperglycemia, hypercatabolism, severe acanthosis nigricans, and hyperandrogenism in women."
    explanation: >-
      Names hyperandrogenism in women as a feature of the syndrome.
- name: Weight Loss
  description: >-
    Marked hypercatabolism with weight loss (cachexia) accompanies the severe
    insulin-resistant, hyperglycemic phase.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
  evidence:
  - reference: PMID:42255432
    reference_title: "Type B insulin resistance with glycemic extremes: a case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She had cachexia, acanthosis nigricans, and persistent hyperglycemia despite intravenous insulin infusion exceeding 4 units/kg/day."
    explanation: >-
      Documents cachexia (weight loss/hypercatabolism) accompanying the hyperglycemic phase.
- name: Autoimmunity
  description: >-
    Coexisting systemic autoimmune disease is a common host context for type B
    insulin resistance; it is represented as a phenotype rather than an external
    environmental exposure.
  phenotype_term:
    preferred_term: Autoimmunity
    term:
      id: HP:0002960
      label: Autoimmunity
  evidence:
  - reference: PMID:27254267
    reference_title: "Type B insulin resistance syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This disorder is most frequently reported in middle-aged black women and is invariably associated with other autoimmune diseases."
    explanation: Narrative review supports structured representation of the autoimmune host context while newer cases caution against treating the demographic as exclusive.
- name: Diabetic Ketoacidosis
  description: >-
    Diabetic ketoacidosis can be an initial manifestation of the severe
    insulin-resistant hyperglycemic phase; it is retained as a directly observed
    rare presentation without a frequency band or a stronger causal edge.
  phenotype_term:
    preferred_term: Diabetic ketoacidosis
    term:
      id: HP:0001953
      label: Diabetic ketoacidosis
  evidence:
  - reference: PMID:42255432
    reference_title: "Type B insulin resistance with glycemic extremes: a case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report a 20-year-old Hispanic woman who presented with diabetic ketoacidosis (DKA), severe refractory hyperglycemia, and extreme insulin resistance requiring high doses of U-500 insulin."
    explanation: Directly documents DKA as the presenting manifestation in a confirmed type B insulin resistance case.
biochemical:
- name: Insulin Receptor Autoantibodies
  notes: >-
    Circulating IgG autoantibodies against the insulin receptor are the defining
    laboratory abnormality; markedly elevated titers confirm the diagnosis and
    fall with successful immunomodulatory therapy.
  evidence:
  - reference: PMID:42438801
    reference_title: "Type B insulin resistance syndrome coexisting with aplastic anemia responsive to early immunosuppressive therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Markedly elevated insulin receptor autoantibody titers (85.9%) confirmed the diagnosis of type B IRS."
    explanation: >-
      Insulin receptor autoantibody titer is the confirmatory diagnostic marker.
- name: Hyperinsulinemia
  notes: >-
    High serum insulin concentrations can accompany both hyperglycemic and
    hypoglycemic phases in the classic phenotype. A rare isolated-hypoglycemia
    subgroup instead has suppressed insulin.
  evidence:
  - reference: PMID:29264467
    reference_title: "Immunosuppressive Therapy in Treatment of Refractory Hypoglycemia in Type B Insulin Resistance: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "high serum insulin levels, and insulin receptor autoantibodies"
    explanation: >-
      Documents high serum insulin levels as a laboratory feature of the syndrome.
- name: Elevated adiponectin
  notes: >-
    Paradoxically elevated adiponectin, often with preserved or elevated C-peptide,
    supports receptor-level severe insulin resistance rather than typical metabolic
    syndrome physiology.
  evidence:
  - reference: PMID:42255432
    reference_title: "Type B insulin resistance with glycemic extremes: a case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Laboratory findings showed elevated C-peptide and adiponectin, with positive antinuclear and anti-Smith ribonucleoprotein antibodies."
    explanation: Directly documents elevated adiponectin and C-peptide in a confirmed TBIR case.
prevalence:
- population: Worldwide
  prevalence_class: UNKNOWN
  notes: >-
    The syndrome is rare, and available literature does not establish a
    denominator-based prevalence estimate or a well-defined natural history.
  evidence:
  - reference: PMID:29264467
    reference_title: "Immunosuppressive Therapy in Treatment of Refractory Hypoglycemia in Type B Insulin Resistance: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The exact prevalence and disease course are not well known because of the rarity of this syndrome."
    explanation: The review explicitly states that prevalence is unknown.
progression:
- phase: High-titer insulin-resistant phase
  age_range: Acquired disease, most often reported in adulthood
  notes: >-
    High antibody titers can produce abrupt or refractory hyperglycemia, extreme
    insulin resistance, cachexia, and very high insulin requirements.
  evidence:
  - reference: PMID:42255432
    reference_title: "Type B insulin resistance with glycemic extremes: a case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She had cachexia, acanthosis nigricans, and persistent hyperglycemia despite intravenous insulin infusion exceeding 4 units/kg/day."
    explanation: A human case documents the severe high-titer clinical phase.
  - reference: PMID:42255432
    reference_title: "Type B insulin resistance with glycemic extremes: a case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These antibodies act as partial agonists, resulting in severe insulin resistance and hyperglycemia at high titer, and hypoglycemia at low titer."
    explanation: Supports the antibody-titer framing of the insulin-resistant phase.
- phase: Low-titer hypoglycemic phase
  age_range: May follow or alternate with the insulin-resistant phase
  notes: >-
    As antibody concentration and functional balance change, patients may
    transition to spontaneous fasting or recurrent hypoglycemia; isolated
    low-insulin hypoglycemia is a rare subgroup.
  evidence:
  - reference: PMID:42255432
    reference_title: "Type B insulin resistance with glycemic extremes: a case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This biphasic glycemic course underscores the complex immunopathophysiology of TBIR."
    explanation: The report explicitly characterizes the hyperglycemia-to-hypoglycemia course as biphasic.
clinical_burden:
  burden_level: HIGH
  rationale: >-
    Extreme insulin resistance may require thousands of insulin units per day,
    while a later hypoglycemic phase can be refractory and fatal. Management
    requires vigilant glucose monitoring and immunosuppression, and historical
    mortality was strongly associated with hypoglycemia despite modern gains.
  evidence:
  - reference: PMID:27254267
    reference_title: "Type B insulin resistance syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Traditionally, the high reported mortality rate was typically attributed to the hypoglycemia."
    explanation: Review supports the high burden and mortality associated with the hypoglycemic phase.
  - reference: PMID:29264467
    reference_title: "Immunosuppressive Therapy in Treatment of Refractory Hypoglycemia in Type B Insulin Resistance: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment in the hyperglycemic phase is usually with high doses of insulin (average, 5100 U/d in some studies)"
    explanation: Supports the exceptionally intensive treatment burden of the hyperglycemic phase.
diagnosis:
- name: Insulin receptor autoantibody testing
  description: >-
    Detection of circulating insulin receptor autoantibodies confirms type B
    insulin resistance in a compatible acquired syndrome of extreme insulin
    resistance, glycemic fluctuation, and autoimmune disease.
  diagnosis_term:
    preferred_term: laboratory procedure
    term:
      id: NCIT:C25294
      label: Laboratory Procedure
  evidence:
  - reference: PMID:42438801
    reference_title: "Type B insulin resistance syndrome coexisting with aplastic anemia responsive to early immunosuppressive therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Markedly elevated insulin receptor autoantibody titers (85.9%) confirmed the diagnosis of type B IRS."
    explanation: A human case directly identifies the confirmatory antibody test.
- name: Clinical and metabolic pattern recognition
  description: >-
    The diagnostic pattern includes extreme insulin resistance or spontaneous
    hypoglycemia, high insulin in the classic phenotype, acanthosis nigricans,
    and a frequent coexisting systemic autoimmune disorder. The rare isolated
    hypoglycemia subgroup may instead have suppressed insulin.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  evidence:
  - reference: PMID:27254267
    reference_title: "Type B insulin resistance syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Typically, refractory transient hyperglycemia and extreme insulin resistance are the cardinal features, but hypoglycemia may also occur."
    explanation: Review states the cardinal clinical-metabolic diagnostic pattern.
  - reference: PMID:37552775
    reference_title: "Systematic Review-Type B Insulin Resistance With Isolated Hypoglycemia and Suppressed Insulin."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Isolated hypoglycemia with low insulin forms a rare subgroup of type B insulin resistance."
    explanation: Systematic review prevents the classic high-insulin pattern from being treated as universal.
  - reference: PMID:29264467
    reference_title: "Immunosuppressive Therapy in Treatment of Refractory Hypoglycemia in Type B Insulin Resistance: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "glucose levels (ranging from hyperglycemia with extreme insulin resistance to intractable hypoglycemia without exogenous insulin administration), high serum insulin levels, and insulin receptor autoantibodies."
    explanation: Human case review supports the classic fluctuating glucose, hyperinsulinemia, and receptor-autoantibody pattern.
  - reference: PMID:29264467
    reference_title: "Immunosuppressive Therapy in Treatment of Refractory Hypoglycemia in Type B Insulin Resistance: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most cases occur in the African American population in association with other underlying autoimmune systemic diseases."
    explanation: Supports systemic autoimmunity and the historically reported demographic as diagnostic context, without treating them as requirements.
  - reference: PMID:29264467
    reference_title: "Immunosuppressive Therapy in Treatment of Refractory Hypoglycemia in Type B Insulin Resistance: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other associated features are hyperandrogenism and acanthosis nigricans"
    explanation: Supports the associated physical findings included in clinical pattern recognition.
notes: >-
  Type B insulin resistance is frequently reported with systemic autoimmune
  disease and historically in middle-aged Black or African American women, but
  recent cases demonstrate that it can occur in younger people and across ethnic
  groups. Coexisting autoimmunity is an associated host context, not an external
  environmental exposure, so it is no longer modeled under `environmental`.
  Evidence for the demographic and autoimmune association includes:
  PMID:27254267 reports that the disorder is most frequently described in
  middle-aged Black women and associated with other autoimmune diseases, while
  PMID:42255432 explicitly notes younger and ethnically diverse presentations.
treatments:
- name: Combination Immunomodulatory Therapy (Rituximab, Cyclophosphamide, Pulse Corticosteroids)
  description: >-
    The NIH combination protocol of rituximab, cyclophosphamide, and pulse
    corticosteroids is aimed at suppressing pathogenic anti-insulin-receptor
    autoantibody production and induced remission in the reported cohort.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: rituximab
      term:
        id: NCIT:C1702
        label: Rituximab
    - preferred_term: cyclophosphamide
      term:
        id: NCIT:C405
        label: Cyclophosphamide
    - preferred_term: corticosteroid
      term:
        id: CHEBI:50858
        label: corticosteroid
  target_mechanisms:
  - target: Pathogenic Anti-Insulin-Receptor Autoantibody Production
    treatment_effect: INHIBITS
    description: >-
      Combination immunomodulation is directed at controlling the pathogenic
      insulin-receptor autoantibody burden.
    evidence:
    - reference: PMID:20484479
      reference_title: "Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This report focuses on seven patients who were treated with an intensive combination protocol of rituximab, cyclophosphamide, and pulse corticosteroids aimed at control of pathogenic autoantibody production."
      explanation: Directly supports the regimen targeting pathogenic autoantibody production.
  evidence:
  - reference: PMID:20484479
    reference_title: "Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This report focuses on seven patients who were treated with an intensive combination protocol of rituximab, cyclophosphamide, and pulse corticosteroids aimed at control of pathogenic autoantibody production."
    explanation: >-
      Describes the combination immunomodulatory protocol and its rationale.
  - reference: PMID:20484479
    reference_title: "Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All seven treated patients achieved remission, defined as amelioration of hyperglycemia, discontinuation of insulin therapy, and resolution of hyperandrogenism."
    explanation: >-
      Documents remission of the metabolic and endocrine phenotype after the protocol.
- name: Glucocorticoid Therapy
  description: >-
    Glucocorticoids are used to suppress autoantibody production; their addition
    can produce rapid clinical improvement and a marked fall in insulin receptor
    autoantibody titers.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: corticosteroid
      term:
        id: CHEBI:50858
        label: corticosteroid
  evidence:
  - reference: PMID:42438801
    reference_title: "Type B insulin resistance syndrome coexisting with aplastic anemia responsive to early immunosuppressive therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The addition of glucocorticoid therapy resulted in rapid clinical improvement and marked reduction in the insulin receptor autoantibody titers"
    explanation: >-
      Documents glucocorticoid-induced improvement and autoantibody titer reduction.
- name: Plasmapheresis
  description: >-
    Therapeutic plasma exchange has been used with variable outcomes in patients
    without spontaneous remission.
  treatment_term:
    preferred_term: Plasmapheresis
    term:
      id: NCIT:C15304
      label: Plasmapheresis
  evidence:
  - reference: PMID:29264467
    reference_title: "Immunosuppressive Therapy in Treatment of Refractory Hypoglycemia in Type B Insulin Resistance: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatments with high-dose steroids, immunosuppressants, and plasmapheresis have been used, with variable outcomes, in patients without spontaneous remission."
    explanation: >-
      Lists plasmapheresis among treatments used, with variable outcomes.
- name: High-Dose Insulin Therapy (Supportive)
  description: >-
    Very high doses of exogenous insulin (including concentrated U-500 insulin
    and intravenous infusion) are used to control hyperglycemia during the
    insulin-resistant phase, though hyperglycemia is often refractory.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: insulin
      term:
        id: CHEBI:145810
        label: insulin
  evidence:
  - reference: PMID:29264467
    reference_title: "Immunosuppressive Therapy in Treatment of Refractory Hypoglycemia in Type B Insulin Resistance: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment in the hyperglycemic phase is usually with high doses of insulin (average, 5100 U/d in some studies)"
    explanation: Human clinical review supports high-dose insulin as supportive therapy during the hyperglycemic phase.
  - reference: PMID:42255432
    reference_title: "Type B insulin resistance with glycemic extremes: a case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She had cachexia, acanthosis nigricans, and persistent hyperglycemia despite intravenous insulin infusion exceeding 4 units/kg/day."
    explanation: >-
      Illustrates the use of very high-dose intravenous insulin and its frequent inadequacy,
      supporting insulin as supportive (not curative) therapy.
- name: Metformin with low-dose semaglutide
  description: >-
    Adjunctive metformin and a GLP-1 receptor agonist can reduce the extraordinary
    insulin requirement during the severe hyperglycemic phase. Evidence is currently
    limited to a case report, so this is supportive rather than disease-modifying care.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:42255432
    reference_title: "Type B insulin resistance with glycemic extremes: a case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Adjunctive therapy with metformin and low-dose semaglutide reduced daily insulin requirements from over 5,000 units to 200 units."
    explanation: Directly reports a large insulin-dose reduction with this adjunctive combination in one TBIR case.
- name: Rituximab and azathioprine immunosuppression
  description: >-
    Rituximab with azathioprine is an alternative reported immunosuppressive
    combination aimed at controlling pathogenic autoantibody production.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Pathogenic Anti-Insulin-Receptor Autoantibody Production
    treatment_effect: INHIBITS
    description: The regimen suppresses the cellular production of pathogenic receptor autoantibodies.
    evidence:
    - reference: PMID:42255432
      reference_title: "Type B insulin resistance with glycemic extremes: a case report and literature review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Subsequent treatment with rituximab and azathioprine led to complete discontinuation of insulin within one week."
      explanation: Human response supports immunosuppression of the pathogenic autoantibody-producing process.
  evidence:
  - reference: PMID:42255432
    reference_title: "Type B insulin resistance with glycemic extremes: a case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Subsequent treatment with rituximab and azathioprine led to complete discontinuation of insulin within one week."
    explanation: Directly reports insulin discontinuation after the regimen.
- name: Diazoxide for recurrent hypoglycemia
  description: >-
    Low-dose diazoxide can be used to control recurrent fasting hypoglycemia in
    the agonistic/low-titer phase when hypoglycemia recurs after steroid taper.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:42255432
    reference_title: "Type B insulin resistance with glycemic extremes: a case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, the course was complicated by serum sickness-like illness and recurrent fasting hypoglycemia, which was managed with glucocorticoids and diazoxide."
    explanation: Directly supports diazoxide in the recurrent hypoglycemic phase of the reported case.
- name: Continuous glucose monitoring
  description: >-
    Continuous glucose monitoring supports dynamic insulin titration across the
    hyperglycemic phase and early detection of transition to severe hypoglycemia.
  treatment_term:
    preferred_term: continuous blood glucose assessment
    term:
      id: NCIT:C92744
      label: Blood Glucose Measurement
  evidence:
  - reference: PMID:42255432
    reference_title: "Type B insulin resistance with glycemic extremes: a case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Continuous glucose monitoring proved essential in guiding therapy and preventing severe hypoglycemia."
    explanation: Directly supports CGM for treatment guidance and safety in biphasic TBIR.
genetic: []
experimental_models: []
animal_models: []
datasets: []
review_notes: >-
  Review was anchored to the acquired autoimmune MONDO entity rather than the
  inherited type A and receptoropathy syndromes. No causal genetic lesion,
  disease-specific public molecular dataset, or evidence-supported experimental
  or animal model was identified in the retained repository sources, so those
  sections are explicitly empty. The pathograph separates high-titer receptor
  antagonism from low-titer receptor agonism and gives every causal edge its own
  evidence. A Monarch D2P audit returned 44 additional Orphanet assertions,
  including many associated autoimmune diseases and nonspecific laboratory
  findings without local source evidence; these were screened rather than
  imported wholesale. DKA was added because the retained case source directly
  documents it, but it remains unwired because that observation alone does not
  establish the exact causal intermediates. Demographic language is descriptive
  rather than exclusive because younger and ethnically diverse cases occur. The
  cellular autoantibody-production node is retained separately from the antibody
  molecule because B/plasma-cell production is the direct target of the reported
  immunomodulatory regimens. Coexisting autoimmunity is structured as a phenotype,
  not an ECTO exposure. Phase-specific supportive therapies and elevated adiponectin
  were added from the retained 2026 case report. No phenotype frequency band was
  assigned without a denominator or source-mapped qualitative frequency.
references:
- reference: PMID:20484479
  title: "Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies."
- reference: PMID:27254267
  title: "Type B insulin resistance syndrome."
- reference: PMID:11889410
  title: "Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective."
- reference: PMID:29264467
  title: "Immunosuppressive Therapy in Treatment of Refractory Hypoglycemia in Type B Insulin Resistance: A Case Report."
- reference: PMID:37552775
  title: "Systematic Review-Type B Insulin Resistance With Isolated Hypoglycemia and Suppressed Insulin."
- reference: PMID:42255432
  title: "Type B insulin resistance with glycemic extremes: a case report and literature review."
- reference: PMID:42438801
  title: "Type B insulin resistance syndrome coexisting with aplastic anemia responsive to early immunosuppressive therapy."
📚

References & Deep Research

References

7
PMID:20484479
Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies.
No top-level findings curated for this source.
PMID:27254267
Type B insulin resistance syndrome.
No top-level findings curated for this source.
PMID:11889410
Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective.
No top-level findings curated for this source.
PMID:29264467
Immunosuppressive Therapy in Treatment of Refractory Hypoglycemia in Type B Insulin Resistance: A Case Report.
No top-level findings curated for this source.
PMID:37552775
Systematic Review-Type B Insulin Resistance With Isolated Hypoglycemia and Suppressed Insulin.
No top-level findings curated for this source.
PMID:42255432
Type B insulin resistance with glycemic extremes: a case report and literature review.
No top-level findings curated for this source.
PMID:42438801
Type B insulin resistance syndrome coexisting with aplastic anemia responsive to early immunosuppressive therapy.
No top-level findings curated for this source.